John CLARKE   SITE

  • Toxins (Basel). 2021;13:537. Microcystin toxicokinetics, molecular toxicology, and pathophysiology in preclinical rodent models and humans. Arman T, Clarke JD. PubMed
  • Pharmacol Rev. 2021;73:847-859. Modeling pharmacokinetic natural product-drug interactions for decision-making: A NaPDI Center Recommended Approach. Cox EJ, Tian DD, Clarke JD, Rettie AE, Unadkat JD, Thummel KE, McCune JS, Paine MF. PubMed
  • Phytother Res. 2021;35:3286-3297. Hepatic organic anion transporting polypeptides mediate disposition of milk thistle flavonolignans and pharmacokinetic silymarin-drug interactions.  Lynch KD, Montonye ML, Tian DD, Arman T, Oyanna VO, Bechtold BJ, Graf TN, Oberlies NH, Paine MF, Clarke JD. PubMed
  • Biochem Pharmacol. 2020;174:113780. Interaction of Oatp1b2 expression and nonalcoholic steatohepatitis on pravastatin plasma clearance. Toth EL, Clarke JD, Csanaky IL, Cherrington NJ. PubMed
  • J Pharmacol Exp Ther. 2019;371:385-393. A pharmacokinetic natural product-disease-drug interaction: A double hit of Silymarin and nonalcoholic steatohepatitis on hepatic transporters in a rat model. Montonye ML, Tian DD, Arman T, Lynch KD, Hagenbuch B, Paine MF, Clarke JD. PubMed
  • Toxicon. 2019;162:1-8. Nonalcoholic fatty liver disease alters microcystin-LR toxicokinetics and acute toxicity. Clarke JD, Dzierlenga A, Arman T, Toth E, Li H, Lynch KD, Tian DD, Goedken M, Paine MF, Cherrington N. PubMed
  • Drug Metab Dispos. 2018;46:1478-1486. Gene-by-environment interaction of Bcrp-/- and Methionine- and Choline-deficient diet-induced onalcoholic steatohepatitis alters SN-38 disposition. Toth EL, Li H, Dzierlenga AL, Clarke JD, Vildhede A, Goedken M, Cherrington NJ. PubMed
  • Liver Int. 2017;37:1074-1081. Impaired N-linked glycosylation of uptake and efflux transporters in human non-alcoholic fatty liver disease. Clarke JD, Novak P, Lake AD, Hardwick RN, Cherrington NJ. PubMed
  • Drug Metab Dispos. 2016;44:1799-1807. Nonalcoholic steatohepatitis modulates membrane protein retrieval and insertion processes. Dzierlenga AL, Clarke JD, Cherrington NJ. PubMed
  • Biochem Pharmacol. 2016;115:144-51. Effect of nonalcoholic steatohepatitis on renal filtration and secretion of adefovirLaho T, Clarke JD, Dzierlenga AL, Li H, Klein DM, Goedken M, Micuda S, Cherrington NJ. PubMed
  • J Pharmacol Exp Ther. 2016;358:246-53. Biliary elimination of Pemetrexed is dependent on Mrp2 in rats: Potential mechanism of variable response in Nonalcoholic Steatohepatitis. Dzierlenga AL, Clarke JD, Klein DM, Anumol T, Snyder SA, Li H, Cherrington NJ. PubMed
  • Diabetes. 2015;64:3305-13 Mechanism of altered Metformin distribution in Nonalcoholic Steatohepatitis. Clarke JD, Dzierlenga AL, Nelson NR, Li H, Werts S, Goedken MJ, Cherrington NJ. PubMed
  • Pharmacol Ther. 2015;151:99-106. Nonalcoholic steatohepatitis in precision medicine: Unraveling the factors that contribute to individual variability. Clarke JD, Cherrington NJ. PubMed
  • J Pharmacol Exp Ther. 2015;352:462-70. Mechanistic basis of altered morphine disposition in nonalcoholic steatohepatitis. Dzierlenga AL, Clarke JD, Hargraves TL, Ainslie GR, Vanderah TW, Paine MF, Cherrington NJ. PubMed
  • Drug Metab Dispos. 2015;43:266-72. Renal xenobiotic transporter expression is altered in multiple experimental models of nonalcoholic steatohepatitis. Canet MJ, Hardwick RN, Lake AD, Dzierlenga AL, Clarke JD, Goedken MJ, Cherrington NJ. PubMed
  • Toxicol Sci. 2014;142:45-55. Increased susceptibility to methotrexate-induced toxicity in nonalcoholic steatohepatitis. Hardwick RN, Clarke JD, Lake AD, Canet MJ, Anumol T, Street SM, Merrell MD, Goedken MJ, Snyder SA, Cherrington NJ. PubMed
  • J Hepatol. 2014;61:139-47. Synergistic interaction between genetics and disease on pravastatin disposition. Clarke JD, Hardwick RN, Lake AD, Lickteig AJ, Goedken MJ, Klaassen CD, Cherrington NJ. PubMed
  • J Pharmacol Exp Ther. 2014;348:452-8. Experimental nonalcoholic steatohepatitis increases exposure to simvastatin hydroxy acid by decreasing hepatic organic anion transporting polypeptide expression. Clarke JD, Hardwick RN, Lake AD, Canet MJ, Cherrington NJ. PubMed
  • Drug Metab Dispos. 2014;42:586-95. Modeling human nonalcoholic steatohepatitis-associated changes in drug transporter expression using experimental rodent models. Canet MJ, Hardwick RN, Lake AD, Dzierlenga AL, Clarke JD, Cherrington NJ. PubMed
  • Drug Metab Dispos. 2014;42:596-602. Selective and cytokine-dependent regulation of hepatic transporters and bile acid homeostasis during infectious colitis in mice. Merrell MD, Nyagode BA, Clarke JD, Cherrington NJ, Morgan ET. PubMed
  • Drug Metab Dispos. 2013;41:353-61. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Reese MJ, Savina PM, Generaux GT, Tracey H, Humphreys JE, Kanaoka E, Webster LO, Harmon KA, Clarke JD, Polli JW.  PubMed
  • Expert Opin Drug Metab Toxicol. 2012;8:349-60. Genetics or environment in drug transport: the case of organic anion transporting polypeptides and adverse drug reactions. Clarke JD, Cherrington NJ. PubMed

PubMed

Spokane, United States

CLARKE JOHN.jpg

Last update: October 2021